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OBJECTIVE
Delayed-release metformin (Met DR) is formulated to deliver the drug to the lower
bowel to leverage the gut-based mechanisms of metformin action with lower
plasma exposure. Met DR was assessed in two studies. Study 1 compared the
bioavailability of single daily doses of Met DR to currently available immediate-
releasemetformin (Met IR) and extended-releasemetformin (Met XR) in otherwise
healthy volunteers. Study 2 assessed glycemic control in subjects with type 2 di-
abetes (T2DM) over 12 weeks.
RESEARCH DESIGN AND METHODS
Study 1 was a phase 1, randomized, four-period crossover study in 20 subjects.
Study 2 was a 12-week, phase 2, multicenter, placebo-controlled, dose-ranging
study in 240 subjects with T2DM randomized to receive Met DR 600, 800, or 1,000
mg administered once daily; blinded placebo; or unblinded Met XR 1,000 or 2,000
mg (reference).
RESULTS
The bioavailability of 1,000 mgMet DR b.i.d. was∼50% that of Met IR andMet XR
(study 1). In study 2, 600, 800, and 1,000 mg Met DR q.d. produced statistically
significant, clinically relevant, and sustained reductions in fasting plasma glucose
(FPG) levels over 12 weeks compared with placebo, with an ∼40% increase in
potency compared withMet XR. The placebo-subtracted changes from baseline in
HbA1c level at 12weeks were consistent with changes in FPG levels. All treatments
were generally well tolerated, and adverse events were consistent with Gluco-
phage/Glucophage XR prescribing information.
CONCLUSIONS
Dissociation of the glycemic effect from plasma exposure with gut-restricted Met
DR provides strong evidence for a predominantly lower bowel-mediated mecha-
nism of metformin action.
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Although metformin was introduced as a
treatment for type 2diabetes (T2DM).50
years ago, the mechanism of metformin
action is still debated (1). Historically, the
glucose-lowering actions of metformin
have been attributed to its effects on mi-
tochondrial function, AMPK, and glucagon
receptor–stimulated adenylate cyclase in
the liver and skeletal muscle, albeit at
suprapharmacological doses (2,3). A re-
cent study (4) in rodents suggests that in-
travenous metformin inhibits the redox
shuttle enzyme mitochondrial glycero-
phosphate dehydrogenase, resulting in
an altered hepatocellular redox state, re-
duced conversion of lactate and glycerol
to glucose, and decreased hepatic gluco-
neogenesis at lower doses than are re-
quired to affect AMPK. However, reports
(5,6) that short-term intravenous metfor-
min administration is less effective than
oral administration in rats and humans
have suggested that the gut may be im-
portant for the glucose-lowering action of
metformin. Gut effects include secretion
of the enteroendocrine L-cell products
glucagon-like peptide 1 (GLP-1) and pep-
tide YY, bile acid metabolism, and the gut
microbiome (7,8).
When currently available metformin
formulations (immediate-release met-
formin [Met IR] and extended-release
metformin [Met XR]) are orally adminis-
tered, the absolute bioavailability is
;50% of the total dose with the majority
of absorption occurring in the duode-
num and jejunum (9–11). Importantly,
as metformin is not metabolized in the
gut (11), ;50% of a typical therapeutic
dose is delivered to the distal small in-
testine where it accumulates in the gut
mucosa at concentrations up to 300
times greater than concentrations in
plasma (12). After a single dose of orally
administered Met IR,;30% of the dose
is recovered in the feces (10). Given that
metformin absorption is transporter
rate limited, lower doses (,1,000 mg)
have higher bioavailability (11) but are
less effective (13). Thus, we speculated
that higher doses of metformin ($1,500
mg) are necessary to “overwhelm” the
transporters in the proximal small intes-
tine and deliver optimally effective
doses of metformin to the lower bowel.
The fact that there is a clear dose re-
sponse for metformin while the phar-
macokinetic (PK)/pharmacodynamic
relationship is weak (14) also supports
the concept that presystemicmechanisms
may be important to its glucose-lowering
effect.
We tested the hypothesis that gut ex-
posure to metformin predominantly ac-
counts for its glucose-lowering effect by
using a delayed-release metformin (Met
DR) formulation that targets the ileum, a
region of the gut where the absorption
of metformin is low (9,11). Met DR tar-
gets the ileum through pH-dependent
dissolution of the tablet without modi-
fying the structure of the metformin
molecule. In this report, we describe
two studies demonstrating that Met
DR has lower bioavailability compared
with Met IR and Met XR in otherwise
healthy subjects (study 1) and that the
delivery of low doses of metformin
(600–1,000 mg) to the lower bowel is
at least as effective as similar doses of
Met XR in lowering plasma glucose levels
over 12 weeks in subjects with T2DM
(study 2).
RESEARCH DESIGN AND METHODS
Met DR tablets were produced accord-
ing to current good manufacturing
practices and comprise a Met IR hydro-
chloride (HCl) core overlaid with a pro-
prietary enteric coat. The enteric coat,
which includes Eudragit polymers and
other commonly used excipients, delays
disintegration and dissolution of the
tablet until it reaches a pH of 6.5 in
the distal small intestine and beyond.
Tablet strengths used included 300
and 500 mg metformin HCl. Placebo
tablets were visually identical but con-
tained no active ingredient. Met IR and
Met XR tablets used as comparator
treatments were commercially avail-
able products (Glucophage; Bristol-
Myers Squibb, New York, NY). Both
study protocols were performed in ac-
cordance with good clinical practice and
were approved by the institutional re-
view boards. All subjects provided writ-
ten informed consent prior to study
enrollment.
Study 1 (clinical trial reg. no.
NCT02291510, clinicaltrials.gov) was a
randomized, four-period, crossover PK
study in 20 otherwise healthy male
and female subjects who were between
19 and 65 years of age and had a BMI of
25–35 kg/m2. All subjects received 1 day
of dosing for each of four treatments
(500 mg Met DR b.i.d., 1,000 mg Met DR
b.i.d., 1,000mgMet IR b.i.d., and2,000mg
Met XR q.d.) in a randomized (1:1:1:1)
sequence, separated by a washout pe-
riod of 3–7 days. Met XR was adminis-
tered once with the evening meal per
the prescribing information (15), and
twice-daily doses of Met DR and Met IR
were administered 12 h apart after
meals. Plasma metformin concentra-
tions were measured over a 36.5-h pe-
riod that included five standardized
meals. PK parameters were determined
using noncompartmental analysis meth-
ods based on the individual data for
plasma metformin concentration over
time for each subject. PK parameters
were analyzed in the evaluable popula-
tion (randomized subjects who com-
pleted all treatment periods consistent
with protocol procedures) using a
mixed-effects model on a natural log
scale with fixed effects for treatment,
period, and sequence and subject within
sequence as a random effect. Results
were exponentiated to obtain the geo-
metric least squares (LS) mean ratios and
corresponding 90% CIs on the original
scale. Using two one-sided t tests with
an a = 0.05 and an assumption that the
within-subject variation would be at
least 25%, this sample size provided
90% power to detect a difference in the
area under the curve (AUC) of at least
25% between 1,000 mg b.i.d. Met DR
and 2,000 mg q.d. Met XR.
Study 2 (clinical trial reg. no.
NCT01819272, clinicaltrials.gov) was a
phase 2, 12-week, randomized, pla-
cebo-controlled, dose-response study
conducted in 240 subjects with T2DM
and an estimated glomerular filtration
rate (eGFR) of $60 mL/min/1.73 m2
based on the Modification of Diet in Re-
nal Disease equation. Subjects were
male or female, between 18 and 65
years of age, had a BMI of 25–45 kg/m2,
and had their T2DM treated with
diet and exercise alone or with metfor-
min and/or a DPP-4 inhibitor (DPP-4i)
only. Subjects were washed out of these
medications for 14–17 days. Other inclu-
sion criteria included an HbA1c level of
7.0–9.5% if treated with diet and exer-
cise alone or 6.0–9.5% if treated with
metformin/DPP-4i, serum creatinine
,1.5 mg/dL (male) or ,1.4 mg/dL (fe-
male), and an eGFR of $60 mL/min/
1.73 m2 prior to randomization. Subjects
were randomized (1:1:1:1:1:1) to one of
six treatment arms in a balancedmanner
stratified by screening HbA1c level (,8%
vs. $8%).
The double-blind treatment consisted
of indistinguishable placebo, or 600,
800, or 1,000 mg Met DR once daily in
the morning. Dosing with the morning
meal was selected based on a previous
trial demonstrating that once-daily dos-
ing in the morning resulted in lower bio-
availabilitywith equivalent fasting plasma
glucose (FPG) lowering than the same to-
tal daily dose (1,000 mg) administered
with the evening meal or split between
the morning and evening meals (clinical
trial reg. no. NCT01804842, clinicaltrials
.gov). Active treatment arms of 1,000
and 2,000 mg Met XR administered
once daily in the evening per prescribing
information (15) were included for refer-
ence. The 2,000 mg Met XR dose was ti-
trated over 3 weeks; no other treatments
were titrated.
In study 2, the primary end point was
the change in FPG level from baseline to
week 4. Secondary end points included
changes in HbA1c and FPG levels from
baseline to week 12 and changes in
FPG from baseline to weeks 4, 8, and
12. The baseline-corrected AUC of the
FPG concentration-time curve at steady
state (AUC4–12wk) was also calculated for
each evaluable subject to integrate the
FPG data collected through 12 weeks
into a single value, with week 4 chosen
as the first value because 2,000 mg Met
XR was titrated over the first 3 weeks.
Fasting (premorning dose) PK and
plasma lactate concentrations were
also measured.
Changes in FPG level from baseline to
subsequent study visits were assessed
using an ANCOVAmodel with treatment
and baseline HbA1c levels (,8% and
$8%) as factors and baseline FPG level
as a covariate. For the change in HbA1c
level, an ANCOVAmodel with treatment
as a factor and baseline HbA1c as a co-
variate was used. Notable departures
from the Gaussian assumption were de-
tected for the change in FPG level for all
active treatment groups. Therefore, the
main analyses used the Kruskal-Wallis
test for comparisons to placebo and
the Hodges-Lehmann method for CIs
around the median differences from
placebo. Analyses of HbA1c used para-
metric methods, as the departure from
the Gaussian assumption for these did
not require alternative methods to be
used.
All analyses for the primary end point
were conducted using the intent-to-treat
(ITT) population (randomized subjects
who received at least one dose of the
study drug) and the evaluable popula-
tions (evaluable populations for weeks
4 and 12 consisted of subjects who com-
pleted the corresponding treatment
period without any major protocol vio-
lations and with nonmissing FPG data at
baseline and the corresponding end
point). A sample size of 40 subjects
per treatment group provided ;80%
power to detect a statistically signifi-
cant difference in week 4 FPG values
between at least one Met DR treatment
group and the placebo group. The cal-
culation was based on a two-sided two
sample t test and a = 0.05 with balanced
randomization, a placebo-subtracted
change from baseline equal to220 mg/dL,
a common SD of 30mg/dL, and amissing
data rate of 10%.
RESULTS
Metformin DR PK (Study 1)
Study 1 randomized 20 subjects, and all
subjects received at least one dose of
the study treatment. Most subjects
were male (70%), white (65%), and not
Hispanic or Latino (85%). The mean age
was 32.2 years, the mean weight was
89.0 kg, and the mean BMI was 29.6
kg/m2. One subject did not complete
all four treatments because of an ad-
verse event (AE) unrelated to study
medication (vessel puncture site hema-
toma). All other subjects completed the
study protocol procedures and were in-
cluded in the evaluable population.
Mean plasma concentration-time
profiles of metformin following single
daily dose administration (up to two
doses) were markedly lower for Met
DR than Met IR and Met XR (Fig. 1A). A
delay in absorption with Met DR was
observed; the median time prior to the
first nonzero concentration ranged from
6 to 7 h after the first (evening) doses of
Met DR compared with,1 h for Met IR
andMet XR. The time to reach peak con-
centrations was greater after the even-
ing dose than the subsequent morning
dose for both Met DR (10 and 6–7 h,
respectively) and Met IR (5 and 3 h, re-
spectively). Peak concentrations of Met
DR twice daily were higher following
evening doses than morning doses
(1,000 mg b.i.d.: 880 vs 604 ng/mL;
500 mg b.i.d.: 538 vs 476 ng/mL). Collec-
tively, these data suggest a diurnal effect
in rate and extent of absorption that is
consistent with slowed transit during the
evening and sleeping hours.
The relative bioavailability and expo-
sure resulting from single daily doses of
Met DR twice daily versus Met IR twice
daily and Met XR once daily are shown
in Fig. 1B. The mean maximal drug con-
centration after dosing was higher for
Met XR once daily (1,688 ng/mL) and
Met IR twice daily (1,328 ng/mL) than
for 1,000 and 500 mgMet DR b.i.d. doses
(905 and 607 ng/mL). The mean AUC
from time of dosing to the last measur-
able concentration was also higher for
the Met XR once-daily dose (16,990 ng3
h/mL) and the Met IR twice-daily dose
(18,710 ng 3 h/mL) than for the 1,000
and 500 mg Met DR b.i.d. dose (9,010
and 6,160 ng3 h/mL). The rate and extent
of exposure (AUC from time of dosing to
the last measurable concentration and
maximal drug concentration after dosing)
from the 1,000 mg Met DR b.i.d. dose
were ;52% and 33% lower, respec-
tively, than with the same dose of Met
IR dose, and ;48% and 47% lower, re-
spectively, than with 2,000 mg Met XR
q.d. dose. The rate and extent of expo-
sure from 500 mg Met DR b.i.d. were
;68% and 55% lower, respectively,
than with the 1,000 mg Met IR b.i.d.
dose, and;65% and 64% lower, respec-
tively, thanwith the 2,000mgMet XR q.d.
dose. The reduction in plasma exposure
with both doses of Met DR was statisti-
cally significant compared with Met IR
and Met XR (P , 0.0001). The PK of
Met DRwas not dose proportional, which
is consistent with the known increased
bioavailability at lower doses. As ex-
pected, the comparison of Met XR to
Met IR demonstrated bioequivalence
based on total exposure.
Metformin DR Dose Response (Study 2)
Study 2 randomly assigned 240 subjects
(39–41 per group) to six treatment
groups. Twenty-eight (11.7%) subjects
discontinued from the study early with
discontinuation rates of 14.6%, 7.7%,
7.5%, 12.5%, 10.0%, and 17.5%, respec-
tively, for placebo, 600 mg Met DR, 800
mg Met DR, 1,000 mg Met DR, 1,000 mg
Met XR, and 2,000 mg Met XR doses
(Supplemental Fig. 1) Themost common
reasons for discontinuation were lost to
follow-up (2.9%), protocol violation
(2.5%), and loss of glucose control
(2.5%). There were no statistically sig-
nificant differences in demographics
between treatment groups. Subjects ex-
hibited relatively good glycemic control at
baseline (Table 1). All other characteris-
tics related to diabetes were generally
similar across treatment arms. Twenty-
five subjects (10.4%) and 44 subjects
(18.3%) were excluded from the week 4
and week 12 evaluable populations,
respectively, prior to unblinding for not
completing the treatment period without
major protocol violations or for having
missing values. The percentage of subjects
included in the week 12 evaluable popula-
tion for each treatment group ranged from
73.2% for the placebo group to 92.5% for
the 800 mg Met DR group.
All active treatment groups had im-
provements in FPG level compared
with placebo at week 4 (Fig. 2A). There
were dose-dependent reductions in me-
dian FPG level; the reduction produced
by the 800 mg Met DR dose was statis-
tically significant compared with that by
placebo. Median reductions for 1,000
and 2,000 mg Met XR at week 4 were
statistically significant. The administra-
tion of 1,000 mg Met DR resulted in a
50% greater median reduction in plasma
glucose levels than 1,000 mg Met XR
and ;72% of the 2,000 mg Met XR ef-
fect. The baseline-corrected AUC4–12wk
for FPG (Fig. 2B) also decreased in a dose-
dependent fashion (4.0, 296.0, 2108.0,
2156.0,298.0, and2215.0mg/dL *week,
respectively, for placebo, 600, 800, and
1,000 mg Met DR and 1,000 and 2,000
mg Met XR doses) with statistically sig-
nificant reductions for all Met DR and
Met XR groups compared with placebo
(all P , 0.05). A dose response in FPG
levels was evident for both Met DR and
Met XR with a left-shifted profile for
Met DR compared with Met XR of
;40%.
LS mean (SE) changes in HbA1c level
from baseline were negligible for all Met
DR treatments and for 1,000 mg Met XR
treatment, while placebo increased the
HbA1c level by 0.45% (0.14). Not surpris-
ingly, the administration of 2,000 mg
Met XR resulted in an LS mean (SE) re-
duction of 0.21 (0.13) from baseline,
since that dose was higher than the
mean dose of metformin that subjects
were receiving prior to the washout
(1,438mg/day). The placebo-subtracted
LS mean (SE) changes from baseline in
HbA1c level at 12 weeks were 20.48%
(0.19), 20.45% (0.18), and 20.35%
(0.19) for 600, 800, and 1,000 mg Met
DR, respectively, and20.45% (0.19) and
20.67% (0.19) for 1,000 and 2,000 mg
Met XR, respectively. All differences
were statistically different from placebo
(P , 0.05), with the exception of 1,000
mg Met DR (P = 0.061).
Steady-state metformin concentra-
tions were achieved by week 2 for all
Met DR groups and the 1,000 mg Met
XR group and byweek 4 for the 2,000mg
Met XR group, which required dose
titration through week 3 (Fig. 2C).
Safety and Tolerability
Consistent with the Glucophage/Gluco-
phage XR prescribing information (15),
Figure 1—Plasmametformin concentrations and bioavailability after administration of a single
daily dose (study 1). A: Mean (SD) plasma metformin concentrations by treatment and time
point. Evaluable population (N = 19). Treatments were administered at t = 0 h (8:00 P.M.) and at
t = 12 h (8:00 A.M.) except for Met XR, which was administered as a single dose at t = 0 (black
arrows). Meals were administered at t = 20.42, 2.08, 11.5, 18.08, and 24.08 h relative to the
first dose (dotted vertical lines). B: Relative bioavailability and exposure of single daily doses of
Met DR b.i.d. vs. Met IR b.i.d. and Met XR q.d. Evaluable population (N = 19). Data are ex-
pressed as the percentage geometric LS mean ratio and the corresponding 90% upper confi-
dence limit. ***P , 0.0001 vs. Met IR or Met XR. t, last quantifiable concentration following
dose administration.
the most common treatment-emergent
AEs (TEAEs) were gastrointestinal in na-
ture. In study 1, the most commonly
reported TEAEs in any treatment group
included diarrhea, nausea, vomiting,
and headache. Most TEAEs were as-
sessed as being unrelated to study treat-
ment and were mild in intensity; there
were no deaths.
In study 2, all active treatments were
well tolerated, and TEAEs were consis-
tent with Glucophage/Glucophage XR
prescribing information (15). However,
the incidence of gastrointestinal TEAEs
was relatively low (compared with pre-
scribing information) in all active treat-
ment groups, with gastrointestinal
TEAEs reported by 7.3%, 12.8%, 17.5%,
15.0%, 17.5%, and 12.5% of subjects, re-
spectively, receiving placebo, 600mgMet
DR, 800 mg Met DR, 1,000 mg Met DR,
1,000 mg Met XR, and 2,000 mg Met XR.
This suggests that the population was tol-
erant to metformin, which is consistent
with 88%of subjects having receivedmet-
formin prior to study enrollment and
washout.
As metformin accumulation can re-
sult in increased lactate production,
which, in turn, increases the risk of the
rare but serious metabolic complication
of lactic acidosis, the effects of Met DR
on plasma lactate levels were also eval-
uated in study 2. Mean lactic acid values
were within normal ranges throughout
the study, but were elevated from base-
line by 0.31–0.33 mmol/L (median
0.19–0.29 mmol/L) for Met XR com-
pared with 0.09–0.12 mmol/L (median
20.22 to 0.22 mmol/L) for Met DR and
0.16 mmol/L (median 0.17 mmol/L) for
placebo (Fig. 3). The lack of change from
baseline in lactate levels for the Met DR
groups most likely reflects lower met-
formin exposure. One subject treated
with 2,000 mg Met XR experienced
moderate blood lactate increases for
16 days (up to 5.9 mmol/L) without
other AEs or changes to the treatment
regimen.
CONCLUSIONS
Metformin is the oldest and most com-
monly prescribed oral glucose-lowering
medication in the world and is
considered a first-line therapy for pa-
tients in whom T2DM is newly diag-
nosed (16). Nevertheless, there is no
consensus on its primary site of action,
although it is generally agreed to have
pleiotropic effects. The fact that metfor-
min is not metabolized in vivo and is
;50% bioavailable (11) allows for al-
most equal exposures in the gut and
plasma with typical dosing; however,
until recently, most studies have fo-
cused on systemically based mecha-
nisms only. The liver has been the
main focus of study, owing to decreased
hepatic glucose output with metformin
(17) and observations of metformin ac-
cumulation in the liver at concentrations
;10 times greater than those in plasma
(18,19). However, metformin also
accumulates in the intestine at concen-
trations 300 times greater than in
plasma (12). Thus, the gut is a major res-
ervoir for metformin exposure and is po-
tentially responsible for much of its
glucose-lowering effects, including en-
hanced secretion of GLP-1 and peptide
YY, which in turn affects systemic mecha-
nisms including reducing hepatic glucose
production through glucagon suppression
and enhanced glucose-dependent insulin
secretion (15,20–23).
While the effects of metformin on in-
creasing GLP-1 secretion have been
known for some time (24–27), its signif-
icance is debated. Interestingly, the in-
crease in plasma GLP-1 levels resulting
from metformin administration is simi-
lar to that of a DPP-4i (20) and thus
could explain much of the glucose-
lowering effect of metformin. In addi-
tion, unlike a DPP-4i that reduces GLP-1
degradation, metformin increases GLP-
1 secretion and thus can significantly in-
crease concentrations local to the L cell,
which may in turn enhance neural signal-
ing in the gut and portal vein to rapidly
regulate glycemic control (28–30).
The current study demonstrates that
metformin primarily restricted to the
gut effectively lowers plasma glucose
levels. The observation that low doses
of Met DR appear to be more effective
than similar doses of the more bioavail-
able Met XR suggests that the gut con-
tribution to glucose lowering may
be more important than systemic





















Age, years 51 6 10 54 6 8 53 6 10 52 6 9 51 6 10 52 6 10 52 6 9
Male sex, % 46 46 32 65 45 47 47
White, black, other,a % 68/27/5 77/23/0 58/33/10 75/23/3 60/35/5 68/30/3 68/28/4
BMI, kg/m2 33.6 6 5.3 33.1 6 5.7 33.5 6 5.9 33.3 6 5.6 32.8 6 5.3 33.7 6 5.2 33.36 5.4
Duration of T2DM, years 7.0 5.9 6.0 5.9 6.6 7.0 6.4
HbA1c, % 7.4 6 1.0 7.5 6 0.9 7.3 6 0.9 7.4 6 1.0 7.4 6 1.0 7.4 6 1.0 7.4 6 0.9
FPG at screening, mg/dL 147 6 37 148 6 43 142 6 35 141 6 30 139 6 34 149 6 41 144 6 37
FPG at baseline, mg/dL 177 6 55 180 6 50 163 6 40 172 6 44 166 6 50 180 6 58 173 6 50
FPG, change from screening to baseline, mg/dL 31 6 45 33 6 44 21 6 26 31 6 34 27 6 44 31 6 34 29 6 38
Patients receiving therapy withMetb prior to
study entry (% IR/% XR) 93 (87/13) 80 (84/16) 95 (84/16) 90(92/8) 85 (82/18) 88 (80/20) 88 (85/15)










Patients with mild renal impairment,c % 34 26 40 33 43 35 35
Data are reported asmean6 SD or percentage of subjects for the ITT population (N = 240), unless otherwise indicated. Other, Asian, Pacific Islander/
Native Hawaiian, American Indian/Alaska Native, or other; qAM, once daily in the morning; qPM, once daily in the evening. aPercentages may
not add up to 100 because of rounding. bIncludes Met IR and Met XR. cMild renal impairment defined as eGFR $60 to ,90 mL/min/1.73 m2.
mechanisms. The apparent increase in
potency was most evident when com-
paring the 600 mg Met DR dose to the
1,000 mg Met XR dose (Fig. 2A and B).
The fact that the administration of 1,000
mg Met DR lowered fasting glucose lev-
els by ;50% more than the same dose
of 1,000 mg Met XR provides further
support of increased potency with Met
DR. This leftward shift of the dose-
response curve is all the more striking
given the ;50% reduction in plasma
metformin exposure observed in study
1 (Fig. 1) and the .75% reduction (Fig.
2C) in fasting metformin concentrations
in study 2 at equally effective doses of
Met DR (600 mg) and Met XR (1,000
mg). These data indicate that the gut
is the primary site of action for the
glucose-lowering effect of metformin
and that plasma exposure is less impor-
tant, at least at these therapeutic doses.
From a mechanistic perspective, a
limitation of the current study is that a
higher Met DR dose was not included.
Since the highest dose ofMetDR (1,000mg)
achieved 70% of the glycemic control
of 2,000 mg Met XR, it is not possible
to determine whether all of the glucose-
lowering effect of metformin can be
explained by lower-bowel gut-based
mechanisms. It is conceivable that the
full metformin effect requires a certain
threshold of upper-bowel metformin ex-
posure and/or plasma exposure along
with the lower-bowel exposure. The du-
odenum has a low density of gut hor-
mone-secreting L cells, and it has been
proposed that the rapid appearance of
GLP-1 following a meal is a result of a
complex integration of proximal and dis-
tal neural and hormonal signaling (31).
However, by virtue of its enteric coating,
Met DR limits both proximal gut expo-
sure and plasma exposure, so it is not
possible to quantitate their potential in-
dividual contributions in these studies.
Our data support the idea that the distal
intestine is responsible for at least 70%
of the maximal glucose-lowering effect
of metformin, and future studies using
higher doses may indicate an even
greater contribution.
Importantly, our data are not in con-
flict with those from a recent report by
Madiraju et al. (4) indicating that intra-
venous metformin administration in
rats reduces the conversion of lactate
and glycerol to glucose, thus decreasing
hepatic gluconeogenesis. Their finding is
Figure 2—Change in FPG and fasting metformin concentrations in the 12-week study (study 2).
A: Median change in FPG level at week 4. Week 4 evaluable population (N = 215). P value from
Kruskal-Wallis test; 95% CI based on Hodges-Lehmann estimation of the median difference vs.
placebo; baseline is defined as the median measurement at day 1. B: Median change in and FPG
AUC4–12wk (mg/dL * week). Week 12 evaluable population (N = 196). *P , 0.05 vs. placebo for
pairwise comparison without adjustment. C: Median fasting plasma metformin concentrations.
Week 12 evaluable population (N = 196).
entirely consistent with multiple obser-
vations in animals and humans (including
our data) that high plasma concentrations
of the guanide/biguanide class increase
plasma lactate levels (14,32–34). While
their study used metformin doses
equivalent to the clinically therapeutic
range (20 and 50 mg/kg), they were ad-
ministered intravenously or intraperito-
neally, which would result in much
higher peak metformin plasma concen-
trations and overall exposures than
would be observed with oral adminis-
tration. Thus, while gut-based mecha-
nisms appear to account for the majority
of the glucose-lowering effect of met-
formin at therapeutic doses, the inhibi-
tion of the redox shuttle enzyme
mitochondrial glycerophosphate dehy-
drogenase may have important glucose-
lowering actions at higher metformin
plasma exposures.
Our data show an increase in plasma
lactate concentrations with Met XR
treatments compared with placebo
that was not observed with any of the
Met DR groups. Conditions that increase
metformin plasma exposure (renal im-
pairment, hepatic insufficiency, or
states of circulatory dysfunction) can in-
crease the risk of metformin-associated
lactic acidosis (MALA), a rare but life-
threatening condition (15). With typical
metformin use, the incidence of MALA
is very low (,10 cases per 100,000
patient-years) (15,35,36). MALA events
that are reported are usually associated
with an elevated metformin dose or
plasma exposure and an intercurrent
event that further disrupts lactate pro-
duction or clearance, such as sepsis, re-
duced tissue perfusion, anoxia, or
impaired hepatic metabolism (15,22,36–
39). Optimization of the presystemic
gut-restricted metformin mechanisms
of action may yield a significant treat-
ment advantage by lowering the risk of
MALA, particularly in at-risk popula-
tions. Of note, simply reducing the
dose of currently available metformin
formulations to reduce the risk of
MALA is not a viable approach because
low doses do not provide optimal glyce-
mic control (13,40). Since the bioavail-
ability of metformin increases with
decreasing dose, the lower bowel is ex-
posed to disproportionately less metfor-
min when doses of #1,000 mg are
administered (11), likely reducing or
eliminating the glucose-lowering contri-
bution of the gut-based mechanisms.
In summary, the delivery of metfor-
min to the lower bowel with Met DR
resulted in a glucose-lowering efficacy
comparable to that with Met XR, but
with lower doses and significantly lower
systemic exposure. These data provide
substantial evidence that currently pre-
scribed metformin doses work pre-
dominantly in the gut and that the
contribution of systemic metformin is
small. Based on its gut-restricted
properties, Met DR may allow for the
metformin treatment of patients with
renal impairment without the risk of
lactic acidosis associated with metfor-
min accumulation.
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